The administration of IL-19 and IL-13 can activate pathways such as STAT3, STAT6, and KLF4 to promote macrophages to perform anti-inflammatory, lipid efflux, efferocytosis and other functions, and anti-IL-1β antibody can inhibit IL-1-mediated chronic inflammation and lipid metabolism disorders, thereby improving the stability of atherosclerotic plaques.363,537–539. The gene discussed is IL1B; the disease is Disorder of lipid metabolism.